fda warning letter bpc-157 2023 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides An FDA Committee Just Voted in Favor of PeptidesDespite the Agency's Opposition FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers KRQE News 13 FDA panel narrowly backs unapproved peptide drugs NBC4 Washington
Pay in 4 interest-free payments of $5.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



